Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer and Dr. Jack Hoppin is Named President of Konica Minolta Precision Medicine
Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately. Dr. Jack Hoppin, co-founder of Invicro, will move on from his role as Invicro’s CEO to be the President of Konica Minolta Precision Medicine (KMPM). Dr. Hoppin will remain on Invicro’s Board of Directors, as well as continue to serve on the KMPM Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191223005320/en/
Invicro LLC Announces Dr. Matthew Silva as New Chief Executive Officer (Photo: Business Wire)
Konica Minolta, Inc. acquired Invicro LLC and Ambry Genetics Corporation in September 2017 to accelerate its strategic vision to transform personalized medicine through the delivery of diagnostic services via genetics, imaging and digital pathology capabilities. Konica Minolta Precision Medicine was formalized as a result of bringing these three entities together.
“It has been an extreme honor to serve as Invicro’s CEO, since co-founding the company in 2008,” stated Dr. Hoppin. “This is an exciting time for Invicro, Ambry and KMPM, as we are all working together to support the medical research community through integrated AI technology platforms that allow molecular-level testing and analysis offering insights to advance translational medicine.”
In his new role, Dr. Hoppin will work to synergize the companies under KMPM to help pharmaceutical sponsors and clinicians accelerate the development of targeted therapies through genetic and molecular profiling.
“I’m looking forward to seeing the next chapter for KMPM and Invicro,” said Mr. Kiyotaka Fujii, president of Konica Minolta Global Healthcare and CEO of KMPM. “As KMPM continues to focus on revolutionizing personalized healthcare via the strengths of Konica Minolta, Invicro and Ambry, Jack will be instrumental in leading and realizing the Konica Minolta Precision Medicine mission. I have full confidence that Matt will seamlessly transition to his new role and continue to lead Invicro into new breakthroughs that will help advance the discovery and development of life-changing medicines.”
Dr. Silva will carry on Invicro’s strategic mission to support the drug discovery and development community. Invicro will continue to leverage its industry-leading imaging, chemistry, and analysis expertise that span discovery through clinical research across multiple therapeutic areas, including the central nervous system, oncology, rare disease, and other systemic diseases. Further, Invicro will continue to invest in its data informatics platforms, enabling management, visualization, and analysis of pathological and radiological imaging data and ensuring alignment with KMPM.
“First, I want to thank Jack for leading Invicro to the great success it is today. I’m honored, humbled and extremely excited to assume this new role and carry on the mission,” said Dr. Silva. “It’s an exciting time for Invicro, as we continue to make great strides with our pharma services capabilities offering imaging biomarkers, advanced analytics, innovative chemistry and technologies, and global core lab services. Thanks to Invicro’s dedicated team and our pharma sponsors—we are together helping the development of new medicines that will improve the lives of patients in need.”
With 20 years of diverse imaging experience, Dr. Silva first joined Invicro in 2012 and most recently was EVP of Scientific Applications, where he led strategic efforts to expand the clinical oncology drug development and clinical trials. Dr. Silva’s pharma industry experience includes scientific and leadership positions at Vertex, Amgen, Millennium and Takeda Pharmaceuticals. Dr. Silva holds a Ph.D. and a Master’s degree in Biomedical Engineering from Worcester Polytechnic Institute.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit www.invicro.com.
About Konica Minolta Precision Medicine
Konica Minolta Precision Medicine, Inc. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. that includes Ambry Genetics Corporation and Invicro LLC. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. For further information, visit: www.KonicaMinoltaPrecisionMedicine.com
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/
VP, Global Marketing
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells3.8.2020 20:03:00 EEST | Press release
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted. The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days.1 Similar results were subsequently seen in more than 15 patients treated under emergency use IND
Panasonic Corporation announces verification of inhibitory effect of hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on novel coronavirus (SARS-CoV-2)3.8.2020 18:47:00 EEST | Press release
Panasonic Corporation today announced that, in collaboration with Mayo Yasugi, Associate Professor, Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, it has verified the inhibitory effect of the hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on the novel coronavirus (SARS-CoV-2). Hydroxyl radicals contained in water are particulate ions containing hydroxyl radicals that are generated by applying a high voltage to moisture in the air. They are characterized by being strongly oxidative and highly reactive. Panasonic has been conducting research on this technology over the past 20 years since 1997, and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*1. In 2012, Panasonic conducted a virus clearance test with a thi
OpenGate Capital Strengthens Management Team with Tenured Chief Financial Officer3.8.2020 17:43:00 EEST | Press release
OpenGate Capital, a global private equity firm, announced today that their senior leadership team has expanded with the addition of Heather Malloy who joined the firm today as Chief Financial Officer based in the firm’s Los Angeles office. Malloy is a tenured, private equity finance executive with an extensive background in corporate strategy, structuring, and systems. She is experienced in control buyouts, senior, junior, and mezzanine debt, structured finance, and asset-backed securities. Prior to joining OpenGate, Malloy was a management consultant at Riva Ridge Management, and she previously served as Chief Operating Officer and Chief Financial Officer at Strattam Capital for six years. In her role at OpenGate Capital, Malloy is responsible for the financial and administrative matters of OpenGate Capital, the funds under OpenGate’s management, and the financial supervision of OpenGate’s global portfolio companies. Andrew Nikou, OpenGate’s Founder and Chief Executive Officer stated,
Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe3.8.2020 17:15:00 EEST | Press release
Alpega, a global provider of cloud-based transportation management systems (TMS), today announced as part of its growing value-adding partner ecosystem, it has partnered with project44, a global leader in supply chain visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005311/en/ Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe (Photo: Business Wire) The partnership delivers real-time truckload tracking integration and serves Alpega customers of all industries and verticals across North America and Europe. “We are happy to join efforts with Alpega to serve our global community of customers,” said Tommy Barnes, Head of Global Network Partnerships at project44. “We want to enable supply chain professionals all over the world to make informed decisions based on high quality, real-time data, and drive more operational efficiencies
JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR3.8.2020 17:00:00 EEST | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new scanning electron microscope (SEM), the JSM-IT700HR for unprecedentedly high throughput in August 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005011/en/ Note: The photo of the instrument is JSM-IT700HR/LA. (Photo: Business Wire) Development background Scanning electron microscopes are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. In addition, SEM applications are expanding to include quality control as well as basic research. The demands are increasing for faster data acquisition of higher-quality SEM images and for easier confirmation of compositional information. Based on our award-winning predecessor of “InTouchScope™” series SEMs, the JSM-IT700HR is equipped with our in-lens Schottky field emission electron gun (FEG). This new powerful SEM satisfies the needs for obser
Immervision Orders Investigation by Ad Hoc Research to Clearly See Smartphone Camera Performance from End Users Point of View3.8.2020 16:00:00 EEST | Press release
Immervision, the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced its 2020 Smartphone Camera survey results in cooperation with Ad Hoc Research. Amid confusing end-user comments on photos and videos and disagreement between phone makers on what has to be done, Immervision decided to investigate what end-user like or don’t like from their phone’s cameras. It revealed no smartphone brand, even the flagship brands, is performing well in consumers’ experience in taking photos. The survey included 1,557 consumers located in California, China and South Korea who selected pictures they preferred amongst 10 images for each of the four scenes comprising city landscape and people. Photos were taken on settings from the same angle and under the same environmental conditions. Results were based on region, age, gender. Data was collected February 20 - March 5, 2020. Ad Hoc Research said, “Our study showed that with current functionalities,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom